Pharmaceutical company KalVista Pharmaceuticals Inc (NASDAQ: KALV) announced on Tuesday that it presented a novel analysis at the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology 2023 International Conference in Singapore.

The analysis characterised hereditary angioedema (HAE) attacks in patients undergoing long-term prophylaxis (LTP) treatments. A systematic literature review of interventional and observational LTP studies indicated that, despite significant reductions in HAE attack frequency with LTP, many patients still experience attacks in various anatomic locations, including potentially life-threatening laryngeal attacks. Long-term attack-free rates in randomised controlled trials are generally low with certain treatments.

KalVista is actively developing sebetralstat as an oral on-demand therapy for HAE attacks, with target enrollment achieved for the phase 3 KONFIDENT clinical trial.

Additionally, the company's oral Factor XIIa inhibitor program holds promise for advancing treatment options for HAE and other diseases with significant unmet needs.